Efficacy and safety of glibenclamide therapy after intracerebral haemorrhage (GATE-ICH): A multicentre, prospective, randomised, controlled, open-label, blinded-endpoint, phase 2 clinical trial

BACKGROUND: Glibenclamide is a promising agent for treating brain oedema, but whether it improves clinical outcomes in patients with intracerebral haemorrhage (ICH) remains unclear. In this study, we aimed to explore the efficacy and safety of glibenclamide treatment in patients with acute ICH. METH...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Jingjing, Song, Changgeng, Li, Deshuai, Yang, Xiai, Yu, Liping, Wang, Kangjun, Wu, Jun, Wang, Xiaofeng, Li, Dongsong, Zhang, Bo, Li, Binyong, Guo, Jun, Feng, Weikui, Fu, Feng, Gu, Xinrong, Qian, Jian, Li, Jialong, Yuan, Xiangjun, Liu, Qiuwu, Chen, Jiang, Wang, Xiaocheng, Liu, Yi, Wei, Dong, Wang, Ling, Shang, Lei, Yang, Fang, Jiang, Wen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9513728/
https://www.ncbi.nlm.nih.gov/pubmed/36177443
http://dx.doi.org/10.1016/j.eclinm.2022.101666

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9513728/
https://www.ncbi.nlm.nih.gov/pubmed/36177443
http://dx.doi.org/10.1016/j.eclinm.2022.101666

Ejemplares similares